Among US men with grade group 1 (GG1) prostate cancer, about 1 in 6 had intermediate- or high-risk disease, along with increased rates of adverse pathology and cancer-specific mortality. This finding ...

Lab service utilizes Envision Science's proprietary biomarkers and technology with a goal of improving diagnosis and grading of prostate cancer The new, tissue-based test service is intended to ...

The precise identification of tumor boundaries during radical prostatectomy remains a major clinical challenge. As positive surgical margins occur in 15–40% of prostate cancer cases, the risk of ...

Grade group 1 prostate cancer assessment should include PSA, stage, and disease volume for accurate risk evaluation. Active surveillance is safe for most low-risk patients, but higher-risk features ...

A new test could be more effective at detecting dangerous prostate cancer than current screening methods, a study suggests.

Malignancy grading of prostate cancer (PCa) is fundamental for risk stratification, patient counseling, and treatment decision-making. Deep learning has shown potential to improve the expert consensus ...

In a study believed to be the first of its kind published, a research team led by Johns Hopkins Medicine provides scientific evidence that a healthy diet may reduce the chance of low risk prostate ...

Galen Prostate by IBEX achieved an AUC of 0.941 for distinguishing between low-grade and high-grade cancer. 50 DeepDX Prostate by Deep Bio achieved a high diagnostic concordance to the reference stand ...

Prostate cancer is the most common cancer among men after skin cancer. Age is a significant risk factor for prostate cancer. Family history and genetic factors play a significant role in prostate ...